Analysts at StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Free Report) in a report issued on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
A number of other brokerages have also recently commented on ALIM. HC Wainwright cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a research report on Tuesday, June 25th. Maxim Group reiterated a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.
View Our Latest Stock Analysis on ALIM
Alimera Sciences Trading Down 0.2 %
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. Research analysts forecast that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Alimera Sciences
A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares during the period. Glazer Capital LLC purchased a new position in Alimera Sciences during the second quarter worth about $3,067,000. Ancora Advisors LLC purchased a new position in Alimera Sciences during the first quarter worth about $915,000. Renaissance Technologies LLC boosted its stake in Alimera Sciences by 3.9% during the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock worth $1,010,000 after buying an additional 6,900 shares during the period. Finally, Deltec Asset Management LLC purchased a new position in Alimera Sciences during the second quarter worth about $690,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
See Also
- Five stocks we like better than Alimera Sciences
- Breakout Stocks: What They Are and How to Identify Them
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- The 3 Best Fintech Stocks to Buy Now
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.